{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:06:50Z","timestamp":1792595210661,"version":"4.5.0"},"reference-count":90,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) are types of membranoproliferative glomerulonephritis classified as C3 glomerulopathies. These conditions are characterized by an increased number of intraglomerular cells and diffuse thickening of the glomerular capillary walls, along with the deposition of C3 and minimal or absent immunoglobulin deposits. The underlying cause of both DDD and C3Gn is an abnormal activation of the alternative complement pathway, which can result from acquired or genetic alteration. In acquired forms of DDD and C3GN, the dysregulation of the alternative pathway is commonly induced by the presence of C3 nephritic factors (C3NeFs), which are autoantibodies that stabilize C3 convertase. Both DDD and C3GN can affect individuals of any age, but DDD is primarily diagnosed in children, whereas C3GN tends to be diagnosed at a significantly higher age. The presenting features of these diseases are variable and may include proteinuria, hematuria, hypertension, or kidney failure. A common finding in these diseases is low serum C3 levels with normal serum C4 levels. Chronic deterioration of renal function is commonly observed in DDD and C3GN, often leading to end-stage renal disease (ESRD), especially in DDD. Kidney transplantation outcomes in patients with these conditions are characterized by histological recurrence, which may contribute to higher rates of allograft failure.<\/jats:p>","DOI":"10.3389\/fmed.2023.1289812","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T12:25:25Z","timestamp":1700828725000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["C3 glomerulopathies: dense deposit disease and C3 glomerulonephritis"],"prefix":"10.3389","volume":"10","author":[{"given":"Claudio","family":"Ponticelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Calatroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Moroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/0090-1229(78)90160-5","article-title":"Immunopathology of membranoproliferative glomerulonephritis with subendothelial deposits (Type I MPGN)","volume":"10","author":"Levy","year":"1978","journal-title":"Clin Immunol Immunopathol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1681\/ASN.2005010078","article-title":"Membranoproliferative glomerulonephritis type II (dense deposit disease): an update","volume":"16","author":"Appel","year":"2005","journal-title":"J Am Soc Nephrol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00433081","article-title":"Basement membrane changes in membranoproliferative glomerulonephritis. II Characterization of a third type by silver impregnation of ultra thin sections","volume":"376","author":"Anders","year":"1977","journal-title":"Virchows Arch A Pathol Anat Histol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/jmg.2006.045328","article-title":"Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome","volume":"44","author":"Servais","year":"2007","journal-title":"J Med Genet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.semnephrol.2011.06.005","article-title":"Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification","volume":"31","author":"Sethi","year":"2011","journal-title":"Semin Nephrol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMra1108178","article-title":"Membranoproliferative glomerulonephritis\u2013a new look at an old entity","volume":"366","author":"Sethi","year":"2012","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: consensus report","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1681\/ASN.2015060612","article-title":"Mayo clinic\/renal pathology society consensus report on pathologic classification, diagnosis, and reporting of GN","volume":"27","author":"Sethi","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00467-011-2059-7","article-title":"Clinical features and outcomes of 98 children and adults with dense deposit disease","volume":"27","author":"Lu","year":"2012","journal-title":"Pediatr Nephrol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2215\/CJN.04700513","article-title":"C3 glomerulopathy: clinicopathologic features and predictors of outcome","volume":"9","author":"Medjeral-Thomas","year":"2014","journal-title":"Clin J Am Soc Nephrol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1681\/ASN.2015020187","article-title":"Dense deposit disease mimicking a renal small vessel vasculitis","volume":"27","author":"Singh","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"B13","first-page":"4","article-title":"Acute renal failure in dense deposit disease: complete recovery after combination therapy with immunosuppressant and plasma exchange","volume":"75","author":"Krmar","year":"2011","journal-title":"Clin Nephrol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s00467-017-3702-8","article-title":"C3 glomerulonephritis with a severe crescentic phenotype","volume":"32","author":"Ravindran","year":"2017","journal-title":"Pediatr Nephrol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.md.0000111061.69212.59","article-title":"Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature","volume":"83","author":"Misra","year":"2004","journal-title":"Medicine."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2009.08.003","article-title":"The dynamic nature of Bruch's membrane","volume":"29","author":"Booij","year":"2010","journal-title":"Prog Retin Eye Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.sjopt.2016.11.005","article-title":"Multimodal imaging of membranoproliferative glomerulonephritis type II","volume":"30","author":"Cebeci","year":"2016","journal-title":"Saudi J Ophthalmol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1053\/j.ajkd.2015.07.009","article-title":"Atlas of Renal Pathology: Dense Deposit Disease","volume":"66","author":"Fogo","year":"2015","journal-title":"Am J Kidney Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/ki.2013.340","article-title":"Toward a working definition of C3 glomerulopathy by immunofluorescence","volume":"85","author":"Hou","year":"2014","journal-title":"Kidney Int."},{"key":"B20","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/ki.2008.657","article-title":"Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway","volume":"75","author":"Sethi","year":"2009","journal-title":"Kidney Int."},{"key":"B21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy - understanding a rare complement-driven renal disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat Rev Nephrol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1172\/JCI32525","article-title":"Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice","volume":"118","author":"Rose","year":"2008","journal-title":"J Clin Invest."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1681\/ASN.2013070732","article-title":"Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN","volume":"25","author":"Wong","year":"2014","journal-title":"J Am Soc Nephrol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s00467-018-3989-0","article-title":"Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy","volume":"34","author":"Noris","year":"2019","journal-title":"Pediatr Nephrol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0022-1759(01)00295-2","article-title":"C3 convertase assay for nephritic factor functional activity","volume":"251","author":"Jelezarova","year":"2001","journal-title":"J Immunol Methods."},{"key":"B26","first-page":"449","article-title":"Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor","volume":"68","author":"Ito","year":"1989","journal-title":"Immunology."},{"key":"B27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000348654","article-title":"C3 glomerulopathy","volume":"181","author":"Servais","year":"2013","journal-title":"Contrib Nephrol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.kint.2017.04.017","article-title":"C5 nephritic factors drive the biological phenotype of C3 glomerulopathies","volume":"92","author":"Marinozzi","year":"2017","journal-title":"Kidney Int."},{"key":"B29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2215\/CJN.07900811","article-title":"Causes of alternative pathway dysregulation in dense deposit disease","volume":"7","author":"Zhang","year":"2012","journal-title":"Clin J Am Soc Nephrol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3389\/fimmu.2019.00886","article-title":"Nephritic factors: an overview of classification, diagnostic tools and clinical associations","volume":"10","author":"Corvillo","year":"2019","journal-title":"Front Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3389\/fimmu.2012.00412","article-title":"Local release of properdin in the cellular microenvironment: role in pattern recognition and amplification of the alternative pathway of complement","volume":"3","author":"Cortes","year":"2012","journal-title":"Front Immunol."},{"key":"B32","first-page":"450","article-title":"C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase","volume":"65","author":"Ng","year":"1986","journal-title":"Clin Exp Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.molimm.2011.04.005","article-title":"Dense deposit disease","volume":"48","author":"Smith","year":"2011","journal-title":"Mol Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.molimm.2010.02.002","article-title":"Anti-factor B autoantibody in dense deposit disease","volume":"47","author":"Strobel","year":"2010","journal-title":"Mol Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1056\/NEJMc1107484","article-title":"Combined C3b and factor B autoantibodies and MPGN type II","volume":"365","author":"Chen","year":"2011","journal-title":"N Engl J Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1056\/NEJMc1309449","article-title":"C4 dense-deposit disease","volume":"370","author":"Sethi","year":"2014","journal-title":"N Engl J Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00467-010-1479-0","article-title":"case of dense deposit disease associated with a group A streptococcal infection without the involvement of C3NeF or complement factor H deficiency","volume":"25","author":"Suga","year":"2010","journal-title":"Pediatr Nephrol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3390\/ijms24098432","article-title":"Clinico-pathogenic similarities and differences between infection-related glomerulonephritis and C3 glomerulopathy","volume":"24","author":"Wada","year":"2023","journal-title":"Int J Mol Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s13730-021-00662-2","article-title":"case of C3 glomerulopathy with nephritis-associated plasmin receptor positivity without a history of streptococcal infection","volume":"11","author":"Asano","year":"2022","journal-title":"CEN Case Rep."},{"key":"B40","doi-asserted-by":"publisher","first-page":"6295543","DOI":"10.1155\/2021\/6295543","article-title":"Mycoplasma pneumoniae infection associated C3 glomerulopathy presenting as severe crescentic glomerulonephritis","volume":"2021","author":"De Silva","year":"2021","journal-title":"Case Rep Nephrol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40620-015-0218-9","article-title":"C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?","volume":"29","author":"Alexander","year":"2016","journal-title":"J Nephrol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1055\/s-0034-1375701","article-title":"Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS)","volume":"40","author":"Sethi","year":"2014","journal-title":"Semin Thromb Hemost."},{"key":"B43","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.kint.2017.10.022","article-title":"C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy","volume":"93","author":"Bomback","year":"2018","journal-title":"Kidney Int."},{"key":"B44","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1053\/j.ajkd.2020.11.011","article-title":"Validation of a histologic scoring index for C3 glomerulopathy","volume":"77","author":"Caravaca-Font\u00e1n","year":"2021","journal-title":"Am J Kidney Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1681\/ASN.2007030356","article-title":"New approaches to the treatment of dense deposit disease","volume":"18","author":"Smith","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00467-013-2711-5","article-title":"Rituximab fails where eculizumab restores renal function in C3nef-related DDD","volume":"29","author":"Rousset-Rouvi\u00e8re","year":"2014","journal-title":"Pediatr Nephrol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00467-013-2748-5","article-title":"Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy","volume":"29","author":"Ozkaya","year":"2014","journal-title":"Pediatr Nephrol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.2215\/CJN.01360215","article-title":"Eculizumab in pediatric dense deposit disease","volume":"10","author":"Oosterveld","year":"2015","journal-title":"Clin J Am Soc Nephrol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00467-017-3619-2","article-title":"C3 glomerulopathy and eculizumab: a report on four paediatric cases","volume":"32","author":"Lebreton","year":"2017","journal-title":"Pediatr Nephrol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMc1111953","article-title":"Eculizumab for the treatment of dense-deposit disease","volume":"366","author":"Vivarelli","year":"2012","journal-title":"N Engl J Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1172\/JCI71866","article-title":"Complement factor H-related hybrid protein deregulates complement in dense deposit disease","volume":"124","author":"Chen","year":"2014","journal-title":"J Clin Invest."},{"key":"B52","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12882-017-0802-4","article-title":"Treating C3 glomerulopathy with eculizumab","volume":"19","author":"Welte","year":"2018","journal-title":"BMC Nephrol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.ekir.2022.07.004","article-title":"Alternative complement pathway inhibition with iptacopan for the treatment of C3 glomerulopathy-study design of the APPEAR-C3G trial","volume":"7","author":"Bomback","year":"2022","journal-title":"Kidney Int Rep."},{"key":"B54","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1159\/000527167","article-title":"Clinical outcomes of patients with C3G or IC-MPGN treated with the factor D inhibitor danicopan: final results from two phase 2 studies","volume":"53","author":"Nester","year":"2022","journal-title":"Am J Nephrol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s40265-021-01560-8","article-title":"Pegcetacoplan: First approval","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs."},{"key":"B56","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1053\/j.ajkd.2018.09.002","article-title":"Kidney transplantation in C3 glomerulopathy: a case series","volume":"73","author":"Regunathan-Shenk","year":"2019","journal-title":"Am J Kidney Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/medsci8040044","article-title":"Treatment of C3 glomerulopathy in adult kidney transplant recipients: a systematic review","volume":"8","author":"Gonzalez Suarez","year":"2020","journal-title":"Med Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.mayocp.2018.05.019","article-title":"C3 glomerulopathy: ten years' experience at mayo clinic","volume":"93","author":"Ravindran","year":"2018","journal-title":"Mayo Clin Proc."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1080\/0886022X.2021.1990949","article-title":"C3 glomerulonephritis associated with monoclonal gammopathy: a retrospective case series study from a single institute in China","volume":"43","author":"Zhang","year":"2021","journal-title":"Ren Fail."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1093\/ndt\/gfab302","article-title":"C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies","volume":"37","author":"Caravaca-Font\u00e1n","year":"2022","journal-title":"Nephrol Dial Transplant."},{"key":"B61","doi-asserted-by":"publisher","first-page":"101331","DOI":"10.1016\/j.smim.2019.101331","article-title":"Complement dysregulation in glomerulonephritis","volume":"45","author":"Kaartinen","year":"2019","journal-title":"Semin Immunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00467-015-3311-3","article-title":"C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum","volume":"31","author":"Al-Ghaithi","year":"2016","journal-title":"Pediatr Nephrol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/IJNRD.S285302","article-title":"C4d at crossroads between post-infectious glomerulonephritis and C3 glomerulopathy","volume":"14","author":"Bashir","year":"2021","journal-title":"Int J Nephrol Renovasc Dis."},{"key":"B64","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/ki.2012.212","article-title":"C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up","volume":"82","author":"Sethi","year":"2012","journal-title":"Kidney Int."},{"key":"B65","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","article-title":"Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome","volume":"71","author":"Iatropoulos","year":"2016","journal-title":"Mol Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"632","DOI":"10.5500\/wjt.v6.i4.632","article-title":"Complement related kidney diseases: recurrence after transplantation","volume":"6","author":"Salvadori","year":"2016","journal-title":"World J Transplant."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.3389\/fimmu.2018.02329","article-title":"Unraveling the molecular mechanisms underlying complement dysregulation by nephritic factors in C3G and IC-MPGN","volume":"9","author":"Donadelli","year":"2018","journal-title":"Front Immunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/ki.2012.250","article-title":"Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation","volume":"82","author":"Paix\u00e3o-Cavalcante","year":"2012","journal-title":"Kidney Int."},{"key":"B69","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrneph.2016.99","article-title":"Anti-complement-factor H-associated glomerulopathies","volume":"12","author":"Durey","year":"2016","journal-title":"Nat Rev Nephrol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1159\/000523998","article-title":"Mycoplasma pneumoniae infection associated with anti-factor H autoantibodies in atypical hemolytic uremic syndrome","volume":"146","author":"Valoti","year":"2022","journal-title":"Nephron."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1681\/ASN.2020081224","article-title":"IgM autoantibodies to complement factor H in atypical hemolytic uremic syndrome","volume":"32","author":"Cugno","year":"2021","journal-title":"J Am Soc Nephrol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1681\/ASN.2016030343","article-title":"Anti-Factor B and Anti-C3b autoantibodies in C3 glomerulopathy and Ig-associated membranoproliferative GN","volume":"28","author":"Marinozzi","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1053\/j.ajkd.2022.12.020","article-title":"C3 Glomerulopathy with concurrent thrombotic microangiopathy: clinical and immunological features","volume":"14","author":"Chabannes","year":"2023","journal-title":"Am J Kidney Dis."},{"key":"B74","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/MNH.0000000000000412","article-title":"Evolving complexity of complement-related diseases: C3 glomerulopathy and atypical haemolytic uremic syndrome","volume":"27","author":"Cook","year":"2018","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"B75","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/bcr-2017-220974","article-title":"Atypical haemolytic uremic syndrome (aHUS) and membranoproliferative glomerulonephritis (MPGN), different diseases or a spectrum of complement-mediated glomerular diseases?","volume":"2017","author":"Ankawi","year":"2017","journal-title":"BMJ Case Rep."},{"key":"B76","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: a consensus report of the international kidney and monoclonal gammopathy research group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/MNH.0000000000000201","article-title":"Spectrum of manifestations of monoclonal gammopathy-associated renal lesions","volume":"25","author":"Sethi","year":"2016","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"B78","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1681\/ASN.2017030258","article-title":"Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies\/immune complex-mediated membranoproliferative GN","volume":"29","author":"Iatropoulos","year":"2018","journal-title":"J Am Soc Nephrol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/j.ekir.2020.09.019","article-title":"Long-term outcomes of c3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis in children kidney","volume":"5","author":"Kirpalani","year":"2020","journal-title":"Int Rep."},{"key":"B81","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.kint.2022.05.027","article-title":"Results from a nationwide retrospective cohort measure the impact of C3 and soluble C5b-9 levels on kidney outcomes in C3 glomerulopathy","volume":"102","author":"Chauvet","year":"2022","journal-title":"Kidney Int."},{"key":"B82","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1053\/j.ajkd.2013.02.370","article-title":"C3 glomerulonephritis associated with monoclonal gammopathy: a case series","volume":"62","author":"Zand","year":"2013","journal-title":"Am J Kidney Dis."},{"key":"B83","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.kint.2018.02.020","article-title":"A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits","volume":"94","author":"Gumber","year":"2018","journal-title":"Kidney Int."},{"key":"B84","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/MNH.0b013e32835da24c","article-title":"Treatment options for C3 glomerulopathy","volume":"22","author":"Nester","year":"2013","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/ki.2015.227","article-title":"Effectiveness of mycophenolate mofetil in C3 glomerulonephritis","volume":"88","author":"Rabasco","year":"2015","journal-title":"Kidney Int."},{"key":"B86","doi-asserted-by":"publisher","first-page":"406","DOI":"10.2215\/CJN.09080817","article-title":"Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: a case series","volume":"13","author":"Avasare","year":"2018","journal-title":"Clin J Am Soc Nephrol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2017.11.019","article-title":"Patterns of clinical response to eculizumab in patients with C3 glomerulopathy","volume":"72","author":"Le Quintrec","year":"2018","journal-title":"Am J Kidney Dis."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.2215\/CJN.15241219","article-title":"Mycophenolate mofetil in C3 glomerulopathy and pathogenic drivers of the disease","volume":"15","author":"Caravaca-Font\u00e1n","year":"2020","journal-title":"Clin J Am Soc Nephrol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1681\/ASN.2020101541","article-title":"Safety and efficacy of daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits","volume":"32","author":"Zand","year":"2021","journal-title":"J Am Soc Nephrol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.2215\/CJN.00280121","article-title":"Recurrent glomerular disease after kidney transplantation: diagnostic and management dilemmas","volume":"16","author":"Uffing","year":"2021","journal-title":"Clin J Am Soc Nephrol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1289812\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T12:25:29Z","timestamp":1700828729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1289812\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":90,"alternative-id":["10.3389\/fmed.2023.1289812"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1289812","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,24]]},"article-number":"1289812"}}